









市场行情
/
股票
/
nasdaq-prok
/

ProKidney Corp

PROK

2.530USD

-0.040-1.56%

收盘 12/26, 16:00（美东）报价延迟15分钟

344.02M总市值

亏损市盈率 TTM



ProKidney Corp

2.530

-0.040-1.56%

概览公司财务分析

概览

公司

财务

分析

关于 ProKidney Corp 公司

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

ProKidney Corp简介



公司代码PROK

公司名称ProKidney Corp

上市日期Jun 30, 2021

CEOCulleton (Bruce)

员工数量204

证券类型Ordinary Share

年结日Jun 30

公司地址2000 Frontis Plaza Blvd

城市WINSTON-SALEM

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编27103

电话13369997028

网址https://prokidney.com/

公司代码PROK

上市日期Jun 30, 2021

CEOCulleton (Bruce)

ProKidney Corp公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

Mr. Ethan Holdaway

Investor Relations

Mr. William F. (Bill) Doyle

Independent Director

Mr. Pablo Legorreta

Chairman of the Board

Dr. Uma Sinha, Ph.D.

Independent Director

Mr. James Coulston, CPA

Chief Financial Officer

Ms. Jennifer Fox

Independent Director

Dr. Alan M. Lotvin, M.D.

Independent Director

Dr. Darin J. Weber, Ph.D.

Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial

Dr. Brian J. G. Pereira, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

Mr. Ethan Holdaway

Investor Relations

Mr. William F. (Bill) Doyle

Independent Director

Mr. Pablo Legorreta

Chairman of the Board

Dr. Uma Sinha, Ph.D.

Independent Director

Mr. James Coulston, CPA

Chief Financial Officer

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Tolerantia LLC

15.98%

Suvretta Capital Management, LLC

8.72%

Control Empresarial de Capitales, S.A. de C.V.

7.58%

Morgan Stanley Investment Management Inc. (US)

4.53%

BlackRock Mexico Operadora SA de CV SOFI

2.42%

其他

60.77%

持股股东

占比

Tolerantia LLC

15.98%

Suvretta Capital Management, LLC

8.72%

Control Empresarial de Capitales, S.A. de C.V.

7.58%

Morgan Stanley Investment Management Inc. (US)

4.53%

BlackRock Mexico Operadora SA de CV SOFI

2.42%

其他

60.77%

股东类型

持股股东

占比

Corporation

23.56%

Hedge Fund

11.03%

Investment Advisor

9.77%

Investment Advisor/Hedge Fund

6.08%

Individual Investor

1.83%

Research Firm

0.90%

Endowment Fund

0.71%

Bank and Trust

0.03%

Family Office

0.02%

其他

46.07%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

180

38.60M

28.59%

-15.99M

2025Q2

187

92.52M

71.43%

-12.19M

2025Q1

188

90.99M

70.46%

-13.35M

2024Q4

184

92.39M

74.12%

+21.48M

2024Q3

176

90.75M

73.53%

+26.28M

2024Q2

216

81.85M

70.67%

+19.77M

2024Q1

231

37.73M

58.52%

-31.32M

2023Q4

239

39.92M

63.74%

-31.95M

2023Q3

236

64.28M

104.12%

-21.16M

2023Q2

223

59.02M

95.83%

-21.49M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Tolerantia LLC

22.62M

16.75%

Jun 03, 2025

Suvretta Capital Management, LLC

12.34M

9.14%

Jun 30, 2025

Control Empresarial de Capitales, S.A. de C.V.

10.72M

7.94%

+2.28M

+27.04%

Apr 22, 2025

Morgan Stanley Investment Management Inc. (US)

5.71M

4.23%

-4.33M

-43.14%

Jun 30, 2025

BlackRock Mexico Operadora SA de CV SOFI

3.43M

2.54%

Aug 31, 2025

Operadora de Fondos GBM S.A.B. de C.V.

2.45M

1.81%

Aug 31, 2025

Bleichroeder LP

2.00M

1.48%

Jun 30, 2025

The Vanguard Group, Inc.

1.57M

1.16%

-3.64M

-69.92%

Jun 30, 2025

Culleton (Bruce)

1.54M

1.14%

+1.54M

Mar 17, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Schwab U.S. Small-Cap ETF

0.01%

ALPS Medical Breakthroughs ETF

Global X Russell 2000 Covered Call ETF

Schwab U.S. Broad Market ETF

ProShares UltraPro Russell2000

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

Avantis US Equity ETF

Global X Russell 2000 ETF

iShares Russell 2000 Growth ETF

Schwab U.S. Small-Cap ETF

占比0.01%

ALPS Medical Breakthroughs ETF

占比0%

Global X Russell 2000 Covered Call ETF

占比0%

Schwab U.S. Broad Market ETF

占比0%

ProShares UltraPro Russell2000

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 ETF

占比0%

Avantis US Equity ETF

占比0%

Global X Russell 2000 ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

ProKidney Corp的前五大股东是谁？



ProKidney Corp 的前五大股东如下：
Tolerantia LLC持有股份：22.62M，占总股份比例：16.75%。
Suvretta Capital Management, LLC持有股份：12.34M，占总股份比例：9.14%。
Control Empresarial de Capitales, S.A. de C.V.持有股份：10.72M，占总股份比例：7.94%。
Morgan Stanley Investment Management Inc. (US)持有股份：5.71M，占总股份比例：4.23%。
BlackRock Mexico Operadora SA de CV SOFI持有股份：3.43M，占总股份比例：2.54%。